SEC Form 4 · accession 0001104659-18-042932
Neos Therapeutics, Inc. · NEOS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerald W. McLaughlin
Officer — Chief Executive Officer · Director
Period of report
Jun 27, 2018
Accepted (ET)
Jun 28, 2018 · 6:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001467652
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.20 | Jun 27, 2018 | A | 600,000 | A | — | Jun 27, 2028 | Common Stock | 600,000 | 600,000 | D |
Explanation of responses
- F1This stock option was granted pursuant to the Company's 2018 Inducement Plan and vests in equal annual installments over a four-year period which began on June 27, 2018.